<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317861</url>
  </required_header>
  <id_info>
    <org_study_id>D5491L00001</org_study_id>
    <secondary_id>RDEA3170-205</secondary_id>
    <nct_id>NCT02317861</nct_id>
  </id_info>
  <brief_title>A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Japanese Adult Male Subjects With Gout or Asymptomatic Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the pharmacodynamics (PD), pharmacokinetics (PK),
      safety, and tolerability of multiple doses of RDEA3170 administered in combination with
      febuxostat compared to RDEA3170 administered alone and febuxostat administered alone in
      Japanese adult male subjects with gout or asymptomatic hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum uric acid level</measure>
    <time_frame>baseline and day 7 on each treatment</time_frame>
    <description>% change per treatment will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary excretion of uric acid</measure>
    <time_frame>baseline and day 7 on each treatment</time_frame>
    <description>Timed urinary uric acid excretion per treatment will be compared</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance of uric acid</measure>
    <time_frame>baseline and day 7 on each treatment</time_frame>
    <description>Renal clearance of uric acid will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional excretion of uric acid</measure>
    <time_frame>baseline and day 7 on each treatment</time_frame>
    <description>Fractional excretion and renal clearance of uric acid will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post‐dose on each treatment</time_frame>
    <description>To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (tmax)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post‐dose on each treatment</time_frame>
    <description>To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post‐dose on each treatment</time_frame>
    <description>To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post‐dose on each treatment</time_frame>
    <description>To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 1 and Day 7 on each treatment</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hematology, serum chemistry, coagulation, electrocardiogram and urinalysis parameters</measure>
    <time_frame>Day 1 and Day 8 on each treatment</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs and physical examination findings</measure>
    <time_frame>Day 1 and Day 8 on each treatment</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day 42 of the study as follow up</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hematology, serum chemistry, coagulation, electrocardiogram and urinalysis parameters</measure>
    <time_frame>Day 42 of the study as follow up</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs and physical examination findings</measure>
    <time_frame>Day 42 of the study as follow up</time_frame>
    <description>To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Urinary pH</measure>
    <time_frame>baseline and day 7 on each treatment</time_frame>
    <description>To evaluate the relationship between the doses of uralyt and urinary pH under the administration of RDEA3170.</description>
  </other_outcome>
  <other_outcome>
    <measure>Deoxyribonucleic acid polymorphism</measure>
    <time_frame>Day 1 of the study as randomization</time_frame>
    <description>To collect and store deoxyribonucleic acid (DNA) for future exploratory research.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum uric acid level</measure>
    <time_frame>Baseline and day 7 on each treatment for cohort 6</time_frame>
    <description>% change per treatment will be compared.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Urinary excretion of uric acid</measure>
    <time_frame>Baseline and day 7 on each treatment for cohort 6</time_frame>
    <description>Timed urinary uric acid excretion per treatment will be compared.</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal clearance of uric acid</measure>
    <time_frame>Baseline and day 7 on each treatment for cohort 6</time_frame>
    <description>Renal clearance of uric acid will be calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fractional excretion of uric acid</measure>
    <time_frame>Baseline and day 7 on each treatment for cohort 6</time_frame>
    <description>Fractional excretion and renal clearance of uric acid will be calculated.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Gout and Asymptomatic Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzbromarone</intervention_name>
    <description>Oral Treatment</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening serum uric acid level ≥ 8 mg/dL;

          -  Body weight ≥ 50 kg and a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2;

          -  Free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  History or suspicion of kidney stones;

          -  Diagnosis of benign prostatic hypertrophy (BPH) or neurogenic bladder or evidence of
             BPH/neurogenic bladder such as thin urinary stream or difficulty in urination;

          -  An estimated creatinine clearance &lt; 60 mL/min calculated by the Cockcroft-Gault
             formula;

          -  QTcF interval (QT interval corrected for heart rate using Fridericia's formula) &gt; 450
             msec at Screening;

          -  Receiving strong or moderate Cytochrome P450 (CYP) 3A inhibitors or p-glycoprotein
             inhibitors, or digoxin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Benzbromarone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 1, 2017</submitted>
    <returned>January 24, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

